Investigational New Drugs

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action
Investigational New Drugs - Tập 15 - Trang 49-59 - 1997
William J. Gradishar
Angiogenesis is a biologic process whereby endothelial cells divide and migrate to form new blood vessels. This process is required in physiological conditions, but is also a necessary requirement for solid tumors to grow and metastasize. Over the last several years, the growth factors that have both a positive and negative influence on tumor angiogenesis have been delineated. Interfering with tum...... hiện toàn bộ
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
Investigational New Drugs - Tập 41 - Trang 541-550 - 2023
Minhong Tang, John Crown, Michael J Duffy
TP53 (p53) and MYC are amongst the most frequently altered genes in cancer. Both are thus attractive targets for new anticancer therapies. Historically, however, both genes have proved challenging to target and currently there is no approved therapy against either. The aim of this study was to investigate the effect of the mutant p53 reactivating drug, COTI-2 on MYC. Total MYC, pSer62 MYC and pThr...... hiện toàn bộ
Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
Investigational New Drugs - Tập 20 - Trang 183-194 - 2002
William D. Figg, Erwin A. Kruger, Douglas K. Price, Sonia Kim, William D. Dahut
Prostate cancer is the most frequentlydiagnosed malignancy and the second mostcommon cause of cancer-related death in menin the United States. Unfortunately, atthe current time, no curative treatmentsare available for metastatic prostatecancer. As is the case for most solidtumors, the recruitment of blood vessels(angiogenesis) is key for the progressionand metastasis of prostate cancer. Inhibition...... hiện toàn bộ
A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
Investigational New Drugs - Tập 40 - Trang 308-313 - 2021
Meijuan Huang, Yongmei Liu, Min Yu, Yanying Li, Yan Zhang, Jiang Zhu, Li Li, You Lu
Background. Anlotinib hydrochloride is an oral small molecule inhibitor of multiple tyrosine kinases, and it has been approved as a third-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) in China. This dose-exploration study was designed to investigate the feasibility of anlotinib in combination with other chemotherapy regimens in patients with nonsquamous NSCLC. Methods....... hiện toàn bộ
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
Investigational New Drugs - Tập 28 - Trang 76-82 - 2009
Nicolas Penel, Jean-Pierre Delord, Marie-Edith Bonneterre, Thomas Bachelot, Isabelle Ray-Coquard, Jean-Yves Blay, Laurent Benjamin Pascal, Cécile Borel, Thomas Filleron, Antoine Adenis, Jacques Bonneterre
Objective Selecting patients for phase 1 studies remains challenging. Given the lack of clear and reliable guidance for the estimation of life expectancy, we retrospectively assessed predictive factors of early death (within 90 days following inclusion) among these patients. Methods Two hundred fifty-seven consecutive cancer patients enrolled in phase I studies investigating cytotoxics at Oscar La...... hiện toàn bộ
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma
Investigational New Drugs - Tập 24 - Trang 89-94 - 2006
Karl D. Lewis, John A. Thompson, Jeffrey S. Weber, William A Robinson, Steven O'Day, Jose Lutzky, Sewa S. Legha, Simon Floret, Francis Ruvuna, Rene Gonzalez
Metastatic melanoma continues to be a very difficult disease to treat. Options are limited and often have very little impact on the course of the disease. The objective of the current study was to evaluate the efficacy and safety of continuously administered Apomine (SR-45023A), a novel bisphosphonate, in patients with previously treated metastatic malignant melanoma. Adult patients with previousl...... hiện toàn bộ
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors
Investigational New Drugs - - 2010
Roos L. Oostendorp, Petronella O. Witteveen, Brian Schwartz, Liia D. Vainchtein, Margaret Schot, A. Nol, Hilde Rosing, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Correlation of the structure of amino-substituted anthraquinones to cytotoxicity in cultured Chinese hamster cells
Investigational New Drugs - Tập 1 - Trang 213-218 - 1983
Bruce F. Kimler, C. C. Cheng, Richard E. Barnes, Mary L. Barnes
A number of substituted anthraquinones (SAQs) are currently being tested as cancer chemotherapeutic agents because of their structural similarity to Adriamycin (ADR) and other DNA-intercalating antibiotics. In this study, the effect of SAQs on the induction of cytotoxicity of asynchronous Chinese hamster cells in culture was studied and compared to those produced by ADR and dihydroxyanthraquinone ...... hiện toàn bộ
Nghiên cứu giai đoạn II về pyrazoloacridine (NSC#366140) ở bệnh nhân ung thư vú di căn Dịch bởi AI
Investigational New Drugs - Tập 29 - Trang 347-351 - 2009
Bhuvaneswari Ramaswamy, Ewa Mrozek, John Philip Kuebler, Tanios Bekaii-Saab, Eric H. Kraut
Mục đích: Pyrazoloacridine (PZA) là một tác nhân nghiên cứu có khả năng liên kết với axit nucleic, ức chế hoạt động của các enzym topoisomerase 1 và 2. Chúng tôi đã tiến hành một nghiên cứu lâm sàng giai đoạn II để xác định hiệu quả và độc tính của PZA ở bệnh nhân ung thư vú di căn (MBC). Thiết kế nghiên cứu: Trong nghiên cứu đa trung tâm giai đoạn II này, bệnh nhân được điều trị với không quá một...... hiện toàn bộ
#Pyrazoloacridine #ung thư vú di căn #nghiên cứu lâm sàng #độc tính #điều trị hóa trị
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
Investigational New Drugs - Tập 34 - Trang 740-749 - 2016
J. E. Grilley-Olson, P. L. Bedard, A. Fasolo, M. Cornfeld, L. Cartee, A. R. Abdul Razak, L.-A. Stayner, Y. Wu, R. Greenwood, R. Singh, C. B. Lee, J. Bendell, H. A. Burris, G. Del Conte, C. Sessa, J. R. Infante
Introduction This Phase Ib trial investigated the safety, tolerability, and recommended phase 2 dose for the pan-PI3K/mTOR inhibitor, GSK2126458 (GSK458), and trametinib combination when administered to patients with advanced solid tumors. Patients and Methods Patients with advanced solid tumors received escalating doses of GSK458 (once or twice daily, and continuous or in...... hiện toàn bộ
Tổng số: 2,526   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10